{"entity":{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","aka":["OncoImmunology","Oncoimmunology"],"tldr":"OncoImmunology is an open access journal devoted to the immune system's role in cancer and to immunotherapy. It is read by tumour immunologists and by clinicians developing immune-based treatments.","summary":"OncoImmunology began in 2012 with Landes Bioscience in Austin, Texas, and has been published by Taylor & Francis since 2015; print issues ceased after the first volume and the journal is online only. It covers cancer immunology and immunotherapy. According to the Directory of Open Access Journals the journal is fully open access, publishes under Creative Commons CC BY or CC BY-NC licences, charges an article processing fee and uses anonymous peer review, with its DOAJ-recorded open access start in 2020. The NLM Catalog lists it as bimonthly, indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/koni"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101570526"},{"label":"DOAJ record","url":"https://doaj.org/toc/2162-402X"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/koni","issn":"2162-4011","scope":"cancer immunology and immunotherapy","access":"open-access","founded":2012,"matchNames":["Oncoimmunology","OncoImmunology"]},"route":"/journals/oncoimmunology/","neighbours":{"collection":[{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"person":[{"id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","route":"/people/eliane-piaggio/"},{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/"}],"paper":[{"id":"paper-gpc3-hcc-oncoimmunology-2016","kind":"paper","name":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","route":"/key-papers/paper-gpc3-hcc-oncoimmunology-2016/"}]}}